Role of the unfolded protein response in tumor cell characteristics and cancer outcome

Current Opinion in Oncology

Volumn 29, Issue 1, 2017, Pages 41-47

  Galmiche, Antoine ^a,b   Sauzay, Chloé ^a,b   Chevet, Eric ^c,d   Pluquet, Olivier ^e  

^a INSTITUT PASTEUR DE LILLE   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d Centre de Lutte Contre Le Cancer Eugène Marquis   (France)

^e UNIV LILLE   (France)

Author keywords

Biomarkers; cancer prognosis; endoplasmic reticulum stress; secretion; unfolded protein response

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN; TUMOR MARKER;

BLOOD BIOCHEMISTRY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; ENDOPLASMIC RETICULUM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SECRETORY PATHWAY; TUMOR CELL; UNFOLDED PROTEIN RESPONSE; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

HUMANS; NEOPLASMS; PROGNOSIS; UNFOLDED PROTEIN RESPONSE;

EID: 84995505450     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000339     Document Type: Review

References (62)

1. Dejeans N, Manié S, Hetz C, et al. Addicted to secrete: novel concepts and targets in cancer therapy. Trends Mol Med 2014; 20:242-250.
2. Dejeans N, Barroso K, Fernandez-Zapico ME, et al. Novel roles of the unfolded protein response in the control of tumor development and aggressiveness. Semin Cancer Biol 2015; 33:67-73.
3. Cherepanova N, Shrimal S, Gilmore R. N-linked glycosylation and homeostasis of the endoplasmic reticulum. Cell Organelles 2016; 41:57-65.
4. Dufey E, Sepulveda D, Rojas-Rivera D, Hetz C. Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 1. ER stress signaling mechanisms: an overview. Am J Physiol Cell Physiol 2014; 307:C582-C594.
5. Manié SN, Lebeau J, Chevet E. Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 3. Orchestrating the unfolded protein response in oncogenesis: an update. Am J Physiol Cell Physiol 2014; 307:C901-C907.
6. Chevet E, Hetz C, Samali A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov 2015; 5:586-597.
7. Wang M, Kaufman RJ. The impact of the endoplasmic reticulum proteinfolding environment on cancer development. Nat Rev Cancer 2014; 14: 581-597.
8. Clarke HJ, Chambers JE, Liniker E, Marciniak SJ. Endoplasmic reticulum stress in malignancy. Cancer Cell 2014; 25:563-573.
9. Labbadia J, Morimoto RI. The biology of proteostasis in aging and disease. Annu Rev Biochem 2015; 84:435-464.
10. Hetz C, Chevet E, Oakes SA. Proteostasis control by the unfolded protein response. Nat Cell Biol 2015; 17:829-838.
11. Wang M, Kaufman RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature 2016; 529:326-335.
12. Hollien J, Weissman JS. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science 2006; 313:104-107.
13. Upton J-P, Wang L, Han D, et al. IRE1a cleaves select microRNAs during ER stress to derepress translation of proapoptotic Caspase-2. Science 2012; 338:818-822.
14. Iwawaki T, Hosoda A, Okuda T, et al. Translational control by the ER transmembrane kinase/ribonuclease IRE1 under ER stress. Nat Cell Biol 2001; 3:158-164.
15. Maurel M, Chevet E, Tavernier J, Gerlo S. Getting RIDD of RNA, IRE1 in cell fate regulation. Trends Biochem Sci 2014; 39:245-254.
16. Shen J, Prywes R. Dependence of site-2 protease cleavage of ATF6 on prior site-1 protease digestion is determined by the size of the luminal domain of ATF6. J Biol Chem 2004; 279:43046-43051.
17. Ye J, Rawson RB, Komuro R, et al. ER stress induces cleavage of membranebound ATF6 by the same proteases that process SREBPs. Mol Cell 2000; 6:1355-1364.
18. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011; 13:184-190.
19. Buszczak M, Signer RAJ, Morrison SJ. Cellular differences in protein synthesis regulate tissue homeostasis. Cell 2014; 159:242-251.
20. Neufeld G, Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev 2006; 25:373-385.
21. Drogat B, Auguste P, Nguyen DT, et al. IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. Cancer Res 2007; 67:6700-6707.
22. Auf G, Jabouille A, Gué rit S, et al. Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad Sci USA 2010; 107:15553-15558.
23. Ghosh R, Lipson KL, Sargent KE, et al. Transcriptional regulation of VEGF-A by the unfolded protein response pathway. PloS One 2010; 5:e9575.
24. Chen X, Iliopoulos D, Zhang Q, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1a pathway. Nature 2014; 508:103-107.
25. McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133:994-1005.
26. Obenauf AC, Zou Y, Ji AL, et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 2015; 520:368-372.
27. Hetz C, Chevet E, Harding HP. Targeting the unfolded protein response in disease. Nat Rev Drug Discov 2013; 12:703-719.
28. Schewe DM, Aguirre-Ghiso JA. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res 2009; 69:1545-1552.
29. Ri M. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Int J Hematol 2016; 104:273-280.
30. Mimura N, Fulciniti M, Gorgun G, et al. Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma. Blood 2012; 119:5772-5781.
31. Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and preplasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013; 24:289-304.
32. Yi P, Higa A, Taouji S, et al. Sorafenib-mediated targeting of the AAA\+ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol Cancer Ther 2012; 11:2610-2620.
33. Houessinon A, Gicquel A, Bochereau F, et al. Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib. Cancer Lett 2016; 370:242-249.
34. Atkins C, Liu Q, Minthorn E, et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2013; 73:1993-2002.
35. Galmiche A, Sauzay C, Houessinon A, et al. Probing tumour proteostasis and the UPR with serum markers. Trends Cancer 2016; 2:219-221.
36. Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol 2012; 57:101-107.
37. Kawaoka T, Aikata H, Murakami E, et al. Evaluation of the mRECIST and afetoprotein ratio for stratification of the prognosis of advanced-hepatocellularcarcinoma patients treated with sorafenib. Oncology 2012; 83:192-200.
38. Chevet E, Fessart D, Delom F, et al. Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. Oncogene 2013; 32:2499-2509.
39. Chung K, Nishiyama N, Yamano S, et al. Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma. Cancer Biomark Sect Dis Markers 2011; 10:101-107.
40. Andruska N, Zheng X, Yang X, et al. Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor a-positive breast cancer.Oncogene 2015; 34:3760-3769.
41. Davies MPA, Barraclough DL, Stewart C, et al. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int J Cancer 2008; 123:85-88.
42. Kim KM, Yu TK, Chu HH, et al. Expression of ER stress and autophagy-related molecules in human nonsmall cell lung cancer and premalignant lesions. Int J Cancer 2012; 131:E362-E370.
43. He Y, Correa AM, Raso MG, et al. The role of PKR/eIF2a signaling pathway in prognosis of nonsmall cell lung cancer. PloS One 2011; 6:e24855.
44. Dalton LE, Clarke HJ, Knight J, et al. The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. Br J Cancer 2013; 108:1340-1347.
45. Kuroda K, Horiguchi A, Asano T, et al. Glucose-regulated protein 78 positivity as a predictor of poor survival in patients with renal cell carcinoma. Urol Int 2011; 87:450-456.
46. Tan SS, Ahmad I, Bennett HL, et al. GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J Pathol 2011; 223:81-87.
47. Pootrakul L, Datar RH, Shi S-R, et al. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res 2006; 12:5987-5993.
48. Thornton M, Aslam MA, Tweedle EM, et al. The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. Int J Cancer 2013; 133:1408-1418.
49. Jin C, Jin Z, Chen N-Z, et al. Activation of IRE1a-XBP1 pathway induces cell proliferation and invasion in colorectal carcinoma. Biochem Biophys Res Commun 2016; 470:75-81.
50. Pluquet O,Dejeans N,Bouchecareilh M,et al. PosttranscriptionalregulationofPER1 underlies the oncogenic function of IREa. Cancer Res 2013; 73:4732-4743.
51. Niu Z, Wang M, Zhou L, et al. Elevated GRP78 expression is associated with poor prognosis in patients with pancreatic cancer. Sci Rep 2015; 5:16067.
52. Pyrko P, Schö nthal AH, Hofman FM, et al. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007; 67:9809-9816.
53. Higa A, Taouji S, Lhomond S, et al. Endoplasmic reticulum stress-activated transcription factor ATF6a requires the disulfide isomerase PDIA5 to modulate chemoresistance. Mol Cell Biol 2014; 34:1839-1849.
54. Wielenga MCB, Colak S, Heijmans J, et al. ER-stress-induced differentiation sensitizes colon cancer stem cells to chemotherapy. Cell Rep 2015; 13:490-494.
55. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7:834-846.
56. Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 2014; 14:611-622.
57. Yeh AC, Ramaswamy S. Mechanisms of cancer cell dormancy: another hallmark of cancer Cancer Res 2015; 75:5014-5022.
58. Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 2006; 66:1702-1711.
59. Schewe DM, Aguirre-Ghiso JA. ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc Natl Acad Sci USA 2008; 105:10519-10524.
60. Druelle C, Drullion C, Deslé J, et al. ATF6a regulates morphological changes associated with senescence in human fibroblasts. Oncotarget 2016; doi:10.
61. 18632/oncotarget.11505. [Epub ahead of print] 61. Coppé J-P, Desprez P-Y, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010; 5:99-118.
62. Bartkowiak K, Kwiatkowski M, Buck F, et al. Disseminated tumor cells persist in the bone marrow of breast cancer patients through sustained activation of the unfolded protein response. Cancer Res 2015; 75:5367-5377.